Background: Cancer patients presenting with COVID-19 have a high risk of death. In this work, predictive factors for survival in cancer patients with suspected SARS-COV-2 infection were investigated.

Figure 1A). In the low-ANC population of the FTD/TPI group, median OS tended to be longer in patients with CIN than in those without CIN [9.9 versus 5.8 months, respectively (HR ¼ 0.49, 95% CI 0.36e0.67)]. Patients with high ANC demonstrated a similar trend [8.0 versus 4.2 months, respectively (HR ¼ 0.45, 95% CI 0.34e0.58)] (Figure 1B). These results suggest that patients receiving FTD/TPI, especially those who develop CIN, have a survival advantage over patients receiving placebo, regardless of baseline ANC.In conclusion, patients with low ANC are expected to have not only a good prognosis but also a survival benefit from FTD/TPI following CIN. The presence or absence of CIN may be a surrogate marker of clinical response to FTD/TPI regardless of baseline ANC, without requiring plasma FTD/ TPI concentration measurements in daily practice.